- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02650401
Estudo de entrectinibe (Rxdx-101) em crianças e adolescentes com tumores localmente avançados ou metastáticos sólidos ou primários do SNC e/ou que não têm opções de tratamento satisfatórias (STARTRK-NG)
Um estudo de fase 1/2, aberto, aumento de dose e expansão de entrectinibe (Rxdx-101) em pediatria com tumores localmente avançados ou metastáticos sólidos ou primários do SNC e/ou que não têm opções de tratamento satisfatórias
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Alemanha, 69120
- Universitaetsklinikum Heidelberg
-
-
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Beijing, China
- Beijing Children's Hospital, Capital Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200082
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
-
-
-
-
Madrid, Espanha, 28009
- Hospital Infantil Universitario Nino Jesus
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92093-0706
- University of California San Diego
-
San Francisco, California, Estados Unidos, 94158
- UCSF Benioff Children's Hospital
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Egleston Children's Hospital at Emory University Atlanta
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University,St. Louis Children's Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health & Science Uni
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38105
- St. Jude Children'S Research Hospital
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Texas Children's Cancer and Hematology Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84113
- Primary Children's Hospital
-
-
-
-
-
Lyon, França, 69373
- Centre Leon Berard
-
Marseille, França, 13385
- Hôpital de la Timone, Oncologie Pédiatrique
-
-
-
-
-
Hong Kong, Hong Kong, 00000
- Hong Kong Children's Hospital
-
-
-
-
Lombardy
-
Milan, Lombardy, Itália, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
-
-
-
-
London, Reino Unido, SW3 6JJ
- Royal Marsden Hospital (Sutton)
-
Newcastle upon Tyne, Reino Unido, NE1 4LP
- Royal Victoria Infirmary
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Disease status:
-
Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1
-
Phase 2 portion:
- Part B: Participants must have measurable or evaluable disease, as defined by RANO
- Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
- Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
- Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
-
-
Tumor type:
-
Phase 1 portion:
* Part A: Relapsed or refractory extracranial solid tumors
-
Phase 2 portion
- Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
- Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
-
-
Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
-
Archival tumor tissue from diagnosis or, preferably, at relapse
-
Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks
-
Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive
-
Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment
-
Adequate organ and neurologic function
-
Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.
-
For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug
Exclusion Criteria:
- Receiving other experimental therapy
- Known congenital long QT syndrome
- History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
- Known active infections
- Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
- Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
- Prior treatment with approved or investigational TRK or ROS1 inhibitors
- Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
- Patients with NB with bone marrow space-only disease
- Incomplete recovery from acute effects of any surgery prior to treatment.
- Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
- Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Extracranial solid tumors harboring NTRK1/2/3,
Arm closed for further enrollment ROS1, ALK non-gene fusion molecular alterations Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Outros nomes:
|
|
Comparador Ativo: CNS tumors harboring- NTRK1/2/3, ROS1, ALK
Arm closed for further enrollment molecular alterations, including gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Outros nomes:
|
|
Comparador Ativo: Neuroblastoma
Arm closed for further enrollment Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Outros nomes:
|
|
Comparador Ativo: Non-neuroblastoma, extracranial solid tumors
Arm closed for further enrollment harboring - NTRK1/2/3, ROS1, ALK gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Outros nomes:
|
|
Comparador Ativo: Any participant unable to swallow capsules
Arm closed for further enrollment Any participant who otherwise meet all other eligibility criteria Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Outros nomes:
|
|
Comparador Ativo: Expansion: CNS tumors harboring NTRK1/2/3, ROS1
gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Outros nomes:
|
|
Comparador Ativo: Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1
NTRK 1,2,3 and ROS1 fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Prazo: Approximately 6 months
|
Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03) |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Prazo: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Prazo: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Prazo: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Prazo: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Cohort B: Objective Response Rate (ORR)
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR |
Approximately 6 months
|
|
Cohort D: ORR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR |
Approximately 6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
Prazo: Approximately 24 months
|
AE, ECG and Labs assessed by NCI CTCAE v4.03 |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F1 Formulation
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using minitablets/F15
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F1 Formulation
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation given intact
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using minitablets/F15
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F1 Formulation
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation given intact
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation administered via feeding tube
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using minitablets/F15
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F1 Formulation
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using minitablets/F15
Prazo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: CBR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: CBR
Prazo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Progression-free Survival (PFS)
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: PFS
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: PFS
Prazo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Overall Survival (OS)
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 |
Approximately 6 months
|
|
Cohort B or E: OS
Prazo: Approximately 6 months
|
Assessed by RANO |
Approximately 6 months
|
|
Cohort A, D, or E: ORR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: ORR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: ORR
Prazo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Time to response (TTR)
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: TTR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: TTR
Prazo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Duration of Response (DOR)
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: DOR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: DOR
Prazo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Prazo: Approximately 6 months
|
Assessed by RANO per the investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Prazo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Prazo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Clinical Trials, Hoffmann-La Roche
Publicações e links úteis
Publicações Gerais
- Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 Oct 3;24(10):1776-1789. doi: 10.1093/neuonc/noac087.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- Pediátrico
- Recaída
- Refratário
- Sarcoma de Ewing
- Meduloblastoma
- Tumor Sólido
- Câncer metastático
- Sarcoma
- Neuroblastoma
- Câncer Papilífero de Tireóide
- Tumores do SNC
- ROS1
- NTRK
- ALK
- Tumores cerebrais
- NTRK1
- NTRK2
- NTRK3
- TRK
- Tirosina quinase
- Rearranjo de genes
- Fibrossarcoma infantil
- Câncer de mama secretor
- Nefroma mesoblástico congênito
- Glioma pontino
- Tumores gliais
- Câncer de Glândula Salivar (MASC)
- Tumor de Wilms (anaplásico)
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças do Sistema Endócrino
- Doenças bucais
- Doenças estomatognáticas
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Processos Patológicos
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Atributos da doença
- Doenças Genéticas, Congênitas
- Neoplasias por Tipo Histológico
- Neoplasias da Tireóide
- Neoplasias das Glândulas Endócrinas
- Neoplasias de Cabeça e Pescoço
- Neoplasias Glandulares e Epiteliais
- Adenocarcinoma
- Processos Neoplásicos
- Neoplasias Urológicas
- Carcinoma
- Neoplasias Neuroepiteliais
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Neoplasias do Sistema Nervoso
- Neoplasias Renais
- Doenças das Glândulas Salivares
- Síndromes Neoplásicas Hereditárias
- Neoplasias de Tecidos Conjuntivos e Moles
- Tumores Neuroectodérmicos Primitivos Periféricos
- Tumores Neuroectodérmicos Primitivos
- Osteossarcoma
- Neoplasias, Tecido Ósseo
- Neoplasias do Tecido Conjuntivo
- Neoplasias Complexas e Mistas
- Doenças da Tireoide
- Adenocarcinoma Papilar
- Neoplasias Bucais
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Câncer de Tireóide Papilar
- Recorrência
- Neoplasia Metástase
- Glioma
- Neuroblastoma
- Sarcoma de Ewing
- Sarcoma
- Neoplasias Cerebrais
- Neoplasias do Sistema Nervoso Central
- Meduloblastoma
- Tumor de Wilms
- Nefroma Mesoblástico
- Neoplasias das Glândulas Salivares
- Entrectinib
Outros números de identificação do estudo
- RXDX-101-03
- CO40778 (Outro identificador: Hoffmann-La Roche)
- 2023-505088-35-00 (Ctis)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .